Paediatric addendum on the CHMP guideline on clinical investigation of medicinal products for the treatment of acute heart failure
| Current effective version |
|
| Reference number | EMA/CHMP/707532/2013 |
| Published | 18/11/2016 |
| Effective from | 01/07/2017 |
| Keywords | Paediatric, drug evaluation, drug approval guideline, heart failure, acute heart failure, clinical evaluation, efficacy criteria, safety aspects |
| Description | This document is an addendum to the guideline on clinical investigation of medicinal products in the treatment of acute heart failure. It highlights differences from adult patients with acute heart failure and points out paediatric-specific aspects. |
Document history
First version Current version |
| Published: 18/11/2016
Published: 18/11/2016
Published: 10/06/2015 Published: 16/01/2013 |
Related content
- Ethical considerations for clinical trials on medical products conducted with the paediatric population
- Clinical investigation of medicinal products for the treatment of acute heart failure
- Clinical trials in small population
- ICH E11 Clinical investigation of medicinal products in the paediatric population
- Impact of liver immaturity when investigating medicinal products intended for neonatal use
- Impact of renal immaturity when investigating medicinal products intended for paediatric use
- Impact of brain immaturity when investigating medicinal products intended for neonatal use
- Investigation of medicinal products in the term and preterm neonate
- Pharmaceutical development of medicines for paediatric use
- Role of pharmacokinetics in the development of medicinal products in the paediatric population